Application status and optimization suggestions of tumor organoids and CAR-T cell co-culture models DOI Creative Commons

Rong-Xuan Ning,

C. Tony Liu,

Shiqi Wang

и другие.

Cancer Cell International, Год журнала: 2024, Номер 24(1)

Опубликована: Март 5, 2024

Tumor organoids, especially patient-derived organoids (PDOs) exhibit marked similarities in histopathological morphology, genomic alterations, and specific marker expression profiles to those of primary tumour tissues. They are applied various fields including drug screening, gene editing, identification oncogenes. However, CAR-T therapy the treatment solid tumours is still at an exploratory stage. Tumour offer unique advantages over other preclinical models commonly used for research, which preservation biological characteristics tissue critical study early-stage therapies. Although some investigators have this co-culture model validate newly targeted cells, optimise existing cells explore combination strategies, there untapped potential today. This review introduces current status application organoid cell recent years commented on limitations co-cultivation model. Meanwhile, we compared with two pre-clinical research. Eventually, combined new progress technologies, optimization suggestions were proposed from five perspectives: preserving or reconstructing tumor microenvironment, systematization, vascularization, standardized culture procedures, expanding resource library, aimed assisting related researchers better utilize models.

Язык: Английский

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition DOI Creative Commons
Antonino Glaviano,

Hannah Lau,

Lukas M. Carter

и другие.

Journal of Hematology & Oncology, Год журнала: 2025, Номер 18(1)

Опубликована: Янв. 13, 2025

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.

Язык: Английский

Процитировано

10
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells DOI Creative Commons
Jianping Li, Zhiwen Xiao,

Donghui Wang

и другие.

Molecular Cancer, Год журнала: 2023, Номер 22(1)

Опубликована: Авг. 30, 2023

Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid tumors. With next-generation sequencing bioinformatics technology, rapid identification prediction tumor-specific antigens (TSAs) has become possible. Compared with tumor-associated (TAAs), highly immunogenic TSAs provide new targets personalized immunotherapy can be used as prospective indicators predicting patient survival, prognosis, immune checkpoint blockade response. Here, characterization neoantigens clinical application neoantigen-based TCR-T strategies are summarized, current status, inherent challenges, translational potential these discussed.

Язык: Английский

Процитировано

27
Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy DOI Creative Commons
Nathan Singh, Marcela V. Maus

Immunity, Год журнала: 2023, Номер 56(10), С. 2296 - 2310

Опубликована: Окт. 1, 2023

Язык: Английский

Процитировано

22
Targeting tumor-infiltrating tregs for improved antitumor responses DOI Creative Commons

Diyuan Qin,

Yugu Zhang,

Pei Shu

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Март 4, 2024

Immunotherapies have revolutionized the landscape of cancer treatment. Regulatory T cells (Tregs), as crucial components tumor immune environment, has great therapeutic potential. However, nonspecific inhibition Tregs in therapies may not lead to enhanced antitumor responses, but could also trigger autoimmune reactions patients, resulting intolerable treatment side effects. Hence, precision targeting and tumor-infiltrating is paramount importance. In this overview, we summarize characteristics subpopulations within microenvironment their inhibitory mechanisms responses. Furthermore, discuss current major strategies regulatory cells, weighing advantages limitations, representative clinical trials We believe that developing specifically target suppress holds promise for advancing immune-based therapies.

Язык: Английский

Процитировано

14
Recent advances and remaining challenges in lung cancer therapy DOI Creative Commons
Tasha Barr, Shoubao Ma, Zhixin Li

и другие.

Chinese Medical Journal, Год журнала: 2024, Номер 137(5), С. 533 - 546

Опубликована: Фев. 7, 2024

Abstract Lung cancer remains the most common cause of death. Given continued research into new drugs and combination therapies, outcomes in lung have been improved, clinical benefits expanded to a broader patient population. However, overall cure survival rates for patients remain low, especially metastatic cases. Among available treatment options, such as surgery, radiation therapy, chemotherapy, targeted alternative immunotherapy has shown be promising. The exponential progress immuno-oncology recent advancements made field will further increase quality life patients. Substantial therapies using tyrosine kinase inhibitors monoclonal antibody immune checkpoint with many US Food And Drug Administration (FDA)-approved targeting programmed cell death ligand-1 protein (e.g., durvalumab, atezolizumab), death-1 receptor nivolumab, pembrolizumab), cytotoxic T-lymphocyte-associated antigen 4 tremelimumab, ipilimumab). Cytokines, vaccines, adoptive T Natural killer mono- combinational are rapidly being studied, yet date, there currently none that FDA-approved cancer. In this review, we discuss current an emphasis on immunotherapy, including challenges future applications.

Язык: Английский

Процитировано

13
CRISPR–Cas9 applications in T cells and adoptive T cell therapies DOI Creative Commons
Xiaoying Chen,

Shuhan Zhong,

Yonghao Zhan

и другие.

Cellular & Molecular Biology Letters, Год журнала: 2024, Номер 29(1)

Опубликована: Апрель 12, 2024

Abstract T cell immunity is central to contemporary cancer and autoimmune therapies, encompassing immune checkpoint blockade adoptive therapies. Their diverse characteristics can be reprogrammed by different challenges dependent on antigen stimulation levels, metabolic conditions, the degree of inflammation. cell-based therapeutic strategies are gaining widespread adoption in oncology treating inflammatory conditions. Emerging researches reveal that clustered regularly interspaced palindromic repeats–associated protein 9 (CRISPR–Cas9) genome editing has enabled cells more adaptable specific microenvironments, opening door advanced therapies preclinical clinical trials. CRISPR–Cas9 edit both primary engineered cells, including CAR-T TCR-T, vivo vitro regulate differentiation activation states. This review first provides a comprehensive summary role its applications studies for We also explore application CRISPR screen high-throughput technology anticipate current limitations CRISPR–Cas9, off-target effects delivery challenges, envisioned improvements related technologies disease screening, diagnosis, treatment.

Язык: Английский

Процитировано

13
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs DOI Creative Commons
Qi Zhao, Hong Zong, Pingping Zhu

и другие.

Experimental Hematology and Oncology, Год журнала: 2024, Номер 13(1)

Опубликована: Янв. 22, 2024

Abstract Cancer immunotherapy has emerged as a promising strategy in the treatment of colorectal cancer, and relapse after tumor attracted increasing attention. stem cells (CSCs), small subset with self-renewal differentiation capacities, are resistant to traditional therapies such radiotherapy chemotherapy. Recently, CSCs have been proven be driving immunotherapy. However, mutual interactions between cancer niche immune largely uncharacterized. In this review, we focus on CSCs, CSC-immune cell CSC-based Colorectal characterized by robust expression surface markers CD44, CD133 Lgr5; hyperactivation stemness-related signaling pathways, Wnt/β-catenin, Hippo/Yap1, Jak/Stat Notch pathways; disordered epigenetic modifications, including DNA methylation, histone modification, chromatin remodeling, noncoding RNA action. Moreover, express abnormal levels immune-related genes MHC checkpoint molecules mutually interact multiple tumorigenesis-related processes, initiation, maintenance, metastasis drug resistance. To date, many targeting evaluated, monoclonal antibodies, antibody‒drug conjugates, bispecific vaccines adoptive therapy, molecule inhibitors. With development CSC-/niche-targeting technology, well integration multidisciplinary studies, novel that eliminate reverse their immunosuppressive microenvironment expected developed for solid tumors, cancer.

Язык: Английский

Процитировано

12
Consensus, debate, and prospective on pancreatic cancer treatments DOI Creative Commons
Junke Wang, Jie Yang, Amol Narang

и другие.

Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)

Опубликована: Окт. 10, 2024

Pancreatic cancer remains one of the most aggressive solid tumors. As a systemic disease, despite improvement multi-modality treatment strategies, prognosis pancreatic was not improved dramatically. For resectable or borderline patients, surgical strategy centered on improving R0 resection rate is consensus; however, role neoadjuvant therapy in patients and optimal chemotherapy with without radiotherapy were debated. Postoperative adjuvant gemcitabine/capecitabine mFOLFIRINOX recommended regardless margin status. Chemotherapy as first-line for advanced metastatic included FOLFIRINOX, gemcitabine/nab-paclitaxel, NALIRIFOX regimens whereas 5-FU plus liposomal irinotecan only standard care second-line therapy. Immunotherapy an innovative although anti-PD-1 antibody currently agent approved by MSI-H, dMMR, TMB-high tumors, which represent very small subset cancers. Combination strategies to increase immunogenicity overcome immunosuppressive tumor microenvironment may sensitize immunotherapy. Targeted therapies represented PARP KRAS inhibitors are also under investigation, showing benefits progression-free survival objective response rate. This review discusses current modalities highlights cancer.

Язык: Английский

Процитировано

11
Advancements in current one-size-fits-all therapies compared to future treatment innovations for better improved chemotherapeutic outcomes: a step-toward personalized medicine DOI
Nadia Μ. Hamdy, Emad B. Basalious,

Mona G. El-Sisi

и другие.

Current Medical Research and Opinion, Год журнала: 2024, Номер 40(11), С. 1943 - 1961

Опубликована: Окт. 16, 2024

The development of therapies followed a generalized approach for long time, assuming that single treatment could effectively address various patient populations. However, recent breakthroughs have revealed the limitations this one-size-fits-all paradigm. More recently, field therapeutics has witnessed shift toward other modules, including cell therapies, high molecular weight remedies, personalized medicines, and gene therapies. Such advancements in therapeutic modules potential to revolutionize healthcare pave way medicines are more efficient with minimal side effects. Cell gained considerable attention regenerative medicine. Stem cell-based instance, hold promise tissue repair regeneration, ongoing research focusing on enhancing their efficacy safety. High drugs like peptides proteins emerged as promising because specificity diverse biological functions. Engineered developed targeted drug delivery, immunotherapy, disease-modulation. In medicine, tailored treatments individuals based specific genetic profiling, lifestyle, biomarkers, disease characteristics all implemented. Clinicians optimize outcomes minimize adverse effects, using mutations, yielding remarkable results. Gene revolutionized disorders by directly targeting underlying abnormalities. Innovative techniques, such CRISPR-Cas9 allowed precise editing, opening up possibilities curing previously incurable conditions. conclusion,

Язык: Английский

Процитировано

10
In Situ Reprogramming of Immune Cells Using Synthetic Nanomaterials DOI

Shihong Nie,

Yuyang Qin,

Liyuan Ou

и другие.

Advanced Materials, Год журнала: 2024, Номер 36(15)

Опубликована: Янв. 17, 2024

In the past decade, adoptive cell therapy with chimeric antigen receptor-T (CAR-T) cells has revolutionized cancer treatment. However, complexity and high costs involved in manufacturing current greatly inhibit its widespread availability access. To address this, situ therapy, which directly reprograms immune inside body, recently been developed as a promising alternative. Here, an overview of recent progress development synthetic nanomaterials is provided to deliver plasmid DNA or mRNA for reprogramming T macrophages, focusing especially on CAR therapies. Also, main challenges are discussed some approaches overcome these barriers fulfill clinical applications proposed.

Язык: Английский

Процитировано

9